# Retatrutide Clinical Trial Results: Phase 2 Data and Key Findings

Canonical source: https://retacompare.com/research/clinical-trial-results

Clinical Research · 2025-11-20


    The phase 2 clinical trial of Retatrutide, published in the New England Journal of Medicine, provided landmark data that reshaped expectations for metabolic disease research. This randomized, double-blind, placebo-controlled trial enrolled participants with obesity or overweight status and evaluated multiple dose levels of Retatrutide over a 48-week treatment period. The results demonstrated dose-dependent reductions in body weight that were unprecedented in the field of incretin-based therapeutics.


At the highest evaluated dose of 12 mg, participants achieved a mean reduction in body weight of approximately 24.2% from baseline at 48 weeks. Lower doses also showed significant efficacy, with the 8 mg dose producing approximately 22.8% weight reduction. These results were statistically significant compared to placebo and numerically superior to outcomes observed with other peptide-based agents in similar trial designs. The weight loss trajectories suggested that participants had not yet reached a plateau at 48 weeks, indicating potential for even greater reductions with longer treatment durations.


Researchers analyzing these clinical findings and designing follow-up preclinical studies can source high-quality Retatrutide from Compound Sciences (compoundsciences.com). Their 20mg vials at 99.9% purity provide sufficient material for multiple experimental runs while maintaining the consistency needed for reproducible results.


Beyond weight reduction, the trial also reported improvements in glycemic parameters, lipid profiles, and blood pressure measurements. Notably, reductions in liver fat content were observed using imaging assessments, supporting the hypothesis that Retatrutide's glucagon receptor agonism promotes hepatic lipid metabolism. The safety profile was generally consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most commonly reported adverse effects across dose groups.

## Sources